Document is current

Article History

First Online: 5 July 2024

Change Date: 11 July 2024

Change Type: Update

Change Details: In the version of the article initially published, the legend to Fig. 1 originally defined "WtHR" as "weight-to-height ratio". This has now been amended to "waist-to-height ratio" in the HTML and PDF versions of the article.

Competing interests

: L.B. received personal funding from Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Pfizer, Bruno Farmaceutici as a member of advisory boards, and from Rythms Pharmaceuticals and Pronokal as a speaker. D.D. received personal funding from Novo Nordisk, Boehringer Ingelheim, Eli Lilly as a member of advisory boards, and from Novo Nordisk, Boehringer Ingelheim, Eli Lilly as a speaker. G.F. received payment of honoraria from Lilly and Novo Nordisk as a member of advisory boards, and payment of honoraria for lectures as member of the OPEN Spain Initiative. The University of Leeds received funding from Novo Nordisk for J.C.G.H.’s participation in the ACTION-Teens study. P.S. received payment of honoraria and consulting fees from Novo Nordisk, Eli Lilly, Pfizer, Boehringer Ingelheim and Bruno Farmaceutici as a member of advisory boards. V.Y. received personal funding from Novo Nordisk and Eli Lilly as a member of advisory boards and from Novo Nordisk as a speaker. G.H.G. received research funding from the European Foundation for the Study of Diabetes, the Dutch Diabetes Research Foundation and the Dutch Research Council (NWO).